Irritable Bowel Syndrome (IBS) is a common disorder that greatly affects quality of life. Several medications have been approved for use in IBS – both constipation (IBS-C) and diarrhea (IBS-D). The American Gastroenterological Association just released guidelines provide evidence-based recommendations for patients.The GameChanger In the last 10 years several pharmacotherapies have been FDA approved for both constipation IBS-C) and IBS-D. Updated guidelines from the AGA review the literature surrounding these and other therapies for evidenced based guidelines update. For example, secretagogues such as linactolide are now first line treatment after PEG laxatives for IBS-C  Show Segments 00:00 – Introduction 01:28 – Irritable Syndrome (IBS) Bowel Background 04:04 – AGA Evidence-Based Recommendations  06:33 – IBS-D Recommendations  14:29 – IBS – D and IBS – C Recommendations 17:39 – IBS – C Recommendations 26:54 – Closing Remarks Host Geoff Wall, PharmD, BCPS, FCCP, CGP Professor of Pharmacy Practice, Drake University Internal Medicine/Critical Care, UnityPoint Health  References and resources:AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation Redeem your CPE or CME creditCPE (Pharmacist)CME (Physician)Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode) Pharmacists: Get a Membership Prescribers: Get a Membership   Continuing Education Information:Learning Objectives:1. Discuss the pharmacologic and non-pharmacologic therapies for treatment of Irritable Bowel Syndrome-Constipation2. Discuss the pharmacologic and non-pharmacologic therapies for treatment of Irritable Bowel Syndrome-Diarrhea0.05 CEU | 0.5 HrsACPE UAN: 0107-0000-22-282-H01-PInitial release date: 08/15/22Expiration date: 08/15/2023Additional CPE & CME details can be found hereFollow CEimpact on Social Media:LinkedInInstagram

Ver todos los episodios